American Thoracic Society - Sanofi Investor Call
Opportunity to bring breakthroughs to large number of
in-need COPD patients
Eligible patients in G7 countries
Large biologics
eligible patient
population in G7
COPD patients
1.7m
countries
Asthma patients
1.9m
Biologics penetration in COPD
>35%
Significant growth of
At
peak
biologics penetration
in COPD expected
No biologics
Today
Source: Sanofi Internal Analysis
Dupixent and itepekimab are under investigation in COPD and not yet approved by any regulatory agency to treat this indication
47 ATS Investor Call
sanofi
Potential first-in-market with DupixentⓇ
•
Impressive data in high need, lethal disease
Addressing ~35% of severe patients at launch
Near-term expansion with itepekimab
• Expanding patient opportunity by >2X
Two complementary, potential
best-in-class agents
•
Reaching 80+% of the severe population
Maximized with proven ability to executeView entire presentation